Overview
Immunicom, Inc. is a pioneering biotechnology company headquartered in San Diego, CA, established in 2013 by Amir Jafri. Specializing in non-pharmaceutical immunotherapies, the company leverages its proprietary Immunopheresis® technology platform to enhance cancer treatment outcomes. By minimizing the side effects and costs associated with conventional treatments, Immunicom is committed to improving the quality of life for patients and increasing therapy response rates.
Leadership
Immunicom's leadership team is a robust collective of seasoned professionals with extensive backgrounds in pharmaceuticals and therapeutic device commercialization:
- Amir Jafri: CEO and Founder, brings a transformative approach to healing methodologies focusing on cost-effectiveness and enhanced patient quality of life.
- Raju Chauhan: Chief Operating Officer, known for delivering innovative technology solutions aligning with the company's strategic objectives.
- Steven Josephs, Ph.D.: Chief Scientist, recognized for his authoritative knowledge in cancer research and pharmaceutical formulations.
- Jennifer Haldeman: Vice President of Commercial Operations, spearheading global strategic commercial initiatives.
Technology and Clinical Trials
At the forefront of immunotherapy innovation, Immunicom's Immunopheresis® therapy, including the LW-02 blood-filtering device, is central to its product line. Despite not yet being FDA-approved, it holds the European CE Mark Certification for aiding in advanced, refractory triple-negative breast cancer treatment. Major technological milestones:
- June 2022: Received a $2 million NIH/NCI grant to initiate a clinical trial at Baylor College of Medicine.
- May 2018: Achieved U.S. FDA Breakthrough Device Designation for cancer treatment.
- Multiple Global Trials: Actively conducting trials on various cancer types, such as non-small cell lung cancer and TNBC, demonstrating diverse oncological applications.
Financial Performance and Funding
With a total funding of $21.8 million secured over four investment rounds, Immunicom benefits from support by investors including Bootstrap Venture Partners and CZV Capital. The financial backing underscores the confidence in the potential of Immunicom's technology and its market viability.
Strategic Collaborations
Partnerships are critical to Immunicom's strategic framework:
- Terumo BCT: Collaboration initiated in August 2021, focused on limited commercial activities of Immunopheresis® products.
- University of California San Diego: Exclusive licensing agreement established in December 2017 for targeted molecule delivery technology.
Recognition and Industry Position
Acknowledged as one of the most attractive workplaces in the U.S., Immunicom continues to establish its position in the biotechnology industry by offering innovative and less invasive therapeutic solutions that address unmet medical needs.
Contact Information
- Address: 6048 Cornerstone Ct W Suite D, San Diego, CA 92121
- Phone for General Inquiries: (657) 202-6388
- Website: [Immunicom, Inc.](https://www.immunicom.com/)
Key Competitors
In the competitive landscape of biotechnology and healthcare, Immunicom faces significant competition from several notable companies:
- Shoreline Biosciences
- IO Biotech
- MaxCyte
- TScan Therapeutics: Focuses on T cell receptor (TCR)-engineered therapies for cancer, noted for its TSC-100 and TSC-101 therapy candidates for treating hematologic malignancies.
- Orpheus Bioscience: A privately-held company, innovating in autoimmune disease treatments with technologies like PantIds.
- Cartesian Therapeutics: Specializes in mRNA cell therapies for autoimmune diseases and cancer, showcasing a significant pipeline with a market cap of $464 million as of February 2025.
- Innovimmune Biotherapeutics: Concentrates on immunomodulatory drugs for oncology and autoimmune diseases, guided by a team from reputed companies like Roche and Pfizer.
- Abcuro: Develops bio-therapeutics targeting autoimmune disorders and cancer, with their leading product candidate being ABC008.
Strategic Insights
To maintain and enhance its market position, Immunicom should focus on:
- Technological Advancements: Continuous improvement and expansion of its immunotherapy platform to remain at the forefront of innovation.
- Collaboration and Partnerships: Form strategic alliances with research entities or technology contributors to boost R&D and product innovation.
- Market Expansion: Consider geographical and segment-wise market expansion strategies through strategic collaborations, paralleling the proactive strategies of competitors.
By analyzing the strategic approaches of its competitors, Immunicom can guide its decisions on R&D focus, potential partnership avenues, and market positioning to strengthen its industry foothold.
